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Abstract Carcinoembryonic antigen (CEACAM5) is
commonly overexpressed in human colon cancer. Several
antigenic peptides recognized by cytolytic CD8+ T-cells
have been identiWed and used in colon cancer phase-I vacci-
nation clinical trials. The HLA-A*0201-binding CEA694–702
peptide was recently isolated from acid eluted MHC-I
associated peptides from a human colon tumor cell line.
However, the immunogenicity of this peptide in humans
remains unknown. We found that the peptide CEA694–702
binds weakly to HLA-A*0201 molecules and is ineVec-
tive at inducing speciWc CD8+ T-cell responses in healthy
donors. Immunogenic-altered peptide ligands with increased
aYnity for HLA-A*0201 were identiWed. Importantly, the
elicited cytolytic T lymphocyte (CTL) lines and clones
cross-reacted with the wild-type CEA694–702 peptide.
Tumor cells expressing CEA were recognized in a peptide
and HLA-A*0201 restricted fashion, but high-CEA
expression levels appear to be required for CTL recogni-
tion. Finally, CEA-speciWc T-cell precursors could be
readily expanded by in vitro stimulation of peripheral
blood mononuclear cell (PBMC) from colon cancer
patients with altered CEA peptide. However, the CEA-
speciWc CD8+ T-cell clones derived from cancer patients
revealed low-functional avidity and impaired tumor-cell
recognition. Together, using T-cells to demonstrate the
processing and presentation of the peptide CEA694-702,
we were able to corroborate its presentation by tumor
cells. However, the low avidity of the speciWc CTLs gen-
erated from cancer patients as well as the high-antigen
expression levels required for CTL recognition pose
serious concerns for the use of CEA694-702 in cancer
immunotherapy.
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Carcinoembryonic antigen (CEA), also designated CD66e
or CEACAM5, belongs to a heterogeneous protein family
that shares common immunoglobulin domains [13]. CEA
confers homophilic and heterophilic cell adhesion and may
contribute to the metastatic progression of tumors [16].
CEA has also been reported to block cell diVerentiation and
to cooperate with other molecules in cellular transformation
[8, 34].
The CEA has been proposed as a potential target antigen
for immunotherapy because it is overexpressed by most
colorectal, gastric, and pancreatic carcinomas, by 50% of
breast cancers, and by 70% of non-small cell lung carcino-
mas [5, 38]. In contrast, CEA is expressed at lower levels in
normal epithelial cells and fetal tissue [23]. Increased levels
of soluble CEA can be detected in the serum from most
patients with CEA-positive tumors, which allows the use of
CEA as surrogate marker for disease progression and
response to therapy [12, 20].
Numerous clinical studies have been performed in the
last few decades targeting CEA for immunotherapy of
colorectal carcinoma. CEA-derived antigens were delivered
as recombinant vectors, peptides, or full-length protein
(for review see [5, 6]). Overall, variable proportions of
patients had positive DTH responses upon vaccination,
and although the majority of vaccinated patients have
been shown to mount CEA-speciWc T-cell and antibody
responses, clinical results have been disappointing. More-
over, only rarely the CEA-speciWc cytolytic T lymphocyte
(CTL) responses correlated with decreased CEA serum
levels or clinical responses. Of note, one study testing
immunization with autologous Flt3L-induced dissociation
complex (DCs) pulsed with the HLA-A*0201-restricted
peptide CEA-CAP1-6D, an analog of CEA605–613
peptide (YLSGANLNL), reported two complete clinical
responses out of 12 metastatic colorectal cancer patients
[10].
A novel HLA-A*0201-restricted peptide was recently
identiWed in eluted peptides from MHC class-I molecules
of a human colon cancer cell line (SW1116) and fresh
human colon cancer tissue [33]. From a list of CEA-derived
peptides predicted to be potential binders of HLA-A*0201,
the authors could only identify one new single peptide
derived from CEA, which was the peptide CEA694–702
(GVLVGVALI). Interestingly, both the cell line and the
fresh tumor tissue presented the same peptide. This bio-
chemical approach is independent of the preexistence of
tumor-speciWc CD8+ T-cells, commonly used for the iden-
tiWcation of novel processed and presented HLA-restricted
epitopes [3]. Although the authors demonstrated the pro-
cessing and presentation of the CEA694–702 peptide, no
immunogenicity data have been reported [33].
In this manuscript, we evaluated the antigenicity and
immunogenicity of the CEA694–702 peptide. We found that
the native CEA694–702 peptide is poorly immunogenic in
healthy donors. In addition, this peptide binds weakly to the
HLA-*0201 (HLA-A2) molecule. In contrast, analogs with
improved binding to HLA-A*0201 molecules were immu-
nogenic. CD8+ T-cell clones cross-reactive with analog
and native peptides were of low to intermediate avidity.
Moreover, these clones recognized tumor cells with
high-CEACAM5 expression, conWrming that CEA694–702
peptide is processed by human tumor cell lines and recog-
nized under certain circumstances. Finally, we found that
CEA694–702-speciWc T-cell responses can be induced in
peripheral blood mononuclear cell (PBMC) in colon cancer
patients. However, in contrast to healthy donor-derived
CTL, CD8+ T-cell clones generated from cancer patients
had lower avidity and were unable to recognize CEA-
expressing tumor cells.
Materials and methods
Synthesis of peptides
Peptides described in Table 2 as well as HIVpol589–597
(IVGAETFYV), FluMA58–66 (GILGFVFTL), and NY-
ESO-1157–165 (SLLMWITQA) were synthesized in an auto-
mated peptide synthesizer 432A (Applied Biosystems,
Weiterstadt, Germany) following the N-(9-Xuorenyl)meth-
oxycarbonyl/tert-butanol strategy. Synthesis products were
analyzed by HPLC (Varian star; Zinsser, Munich, Germany)
and MALDI-TOF mass spectrometry (G2025A; Hewlett-
Packard, Waldbronn, Germany). Peptides were puriWed by
preparative HPLC and dissolved in DMSO to a Wnal
concentration of 10 mM.
Patients
Peripheral blood mononuclear cells of HLA-A*0201 colon
cancer patients were obtained after informed consent. The
study protocol was approved by the Ludwig Institute for
Cancer Research protocol review committee, as well as by
the medical and ethical committees of the University Hos-
pital (Lausanne, Switzerland). All patients had primary
colorectal adenocarcinomas and had not been enrolled in
any adjuvant therapy at the time of blood sampling.
Major histocompatibility complex/peptide multimers 
and monoclonal antibodies
Phycoerythrin-labeled HLA-A2/peptide multimers [1] were
synthesized around CEA694–702 peptide and designed peptide
analogs. The cut-oV value for detection of antigen-speciWc123
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mined by Xow cytometry analysis of CD8+ T-cells from
HLA-A2+ and HLA-A2¡ human healthy donors stained
with the multimers. Monoclonal antibodies (mAbs) were
from Becton Dickinson, San Jose, CA, USA. Dead cells, in
all situations, were electronically excluded by Propidium
Iodine staining.
Cell lines
Human colon cell line SW1116 was the kind gift from
H.G. Rammensee (Universitaet Tuebingen, Tuebingen, Ger-
many). Human colon cell lines SW403, SW480, COLO201,
SW620, LOVO, HCT-116, T84; gastric cancer cell line
KATOIII; and NK-sensitive cell line K562 were bought
from ATCC, Molsheim, France. Na8MEL was the kind gift
from Francine Jotereau (INSERM, Nantes, France) and
Me 290 melanoma cell line was generated from a mela-
noma patient (LAU 203) by Donata Rimoldi (Ludwig
Institute for Cancer Research, Lausanne Branch, Switzer-
land—[40]). All tumor cell lines were used in CTL assays
at exponential phase of cell culture growth and at »80%
conXuence.
Measurement of peptide relative aYnity to HLA-A*0201
The protocol used was as previously described [39] and
applied elsewhere [2, 3, 9]. BrieXy, T2-cells were incubated
at 37°C for 16 h with peptides at concentrations ranging
from 100 to 0.1 M, and then stained with BB7.2 mAb [25]
to quantify the surface expression of HLA-A*0201. For
each peptide concentration, HLA-A2-speciWc staining was
calculated as the % of the staining obtained in the presence
of 100 M of the reference peptide (HIVpol589–597;
IVGAETFYV). The RA score is the ratio of the concentra-
tion of each peptide to the concentration of the reference
peptide that induces 20% of the HLA-A2 expression; the
lower the RA is, the stronger the peptide binds to HLA-A2.
The mean RA for each peptide was determined from at
least three independent experiments. In all experiments,
20% of HLA-A2 expression using the reference peptide
was obtained at concentrations of 1–3 M.
Assessment of peptide/HLA-A*0201 complex stability
As previously described [39], T2-cells were incubated
overnight with 100 M of each peptide at 37°C in serum-
free medium. The cells were then incubated with Brefeldin
A (Sigma-Aldrich, St. Louis, MO, USA) at 10 g/ml for
1 h, washed, incubated at 37°C during 0, 1, 2, 4, or 6 h in
the presence of Brefeldin A (50 ng/ml) and Wnally stained
with BB7.2 moAb. For each time point, peptide-induced
HLA-A2 expression was calculated as: mean Xuorescence
of peptide-incubated T2-cells—mean Xuorescence of T2-
cells treated in similar conditions in the absence of peptide.
DC50 DC was deWned as the time required for the loss of
50% of the HLA-A*0201/peptide complexes stabilized at
t = 0 h.
In vitro expansion of circulating antigen speciWc CD8+ T 
lymphocytes
Peripheral blood mononuclear cells were isolated by Ficoll-
Hypaque (Beckman-Coulter, Fullerton, CA, USA) from the
blood of human healthy donors. For generation of autolo-
gous dendritic (DC) cells, PBMCs were allowed to adhere
into Petri-dishes during 2 h at 37°C. Adherent cells were
incubated with 700 IU/ml of Granulocyte-Macrophage Col-
ony Stimulating Factor (R&D Systems, Minneapolis, MN,
USA) and 1,000 IU/ml of IL-4 (R&D Systems) in CTL cul-
ture medium [RPMI 1640 (Invitrogen, Basel, Switzerland ),
8% pooled human serum, Penicilin/Streptavidin (Invitro-
gen), 50 M -mercaptoethanol (Sigma)]. CD8+ T-cells
were puriWed from non-adherent PBMC by negative selec-
tion using immunomagnetic beads (Miltenyi, Bergisch
Gladbach, Germany) following the manufacturer’s instruc-
tions. For priming, DC were extensively washed and pulsed
at least during 2 h with 10 M of peptide in serum-free
media. Pulsed DCs were later maturated with LPS (Sigma)
at 5 g/ml overnight. Co-culture of DCs with autologous
CD8+ -puriWed T-cells was done at 1:5 ratio in CTL culture
medium. IL-2 (Proleukin, Roche, Switzerland) at 20 IU/ml
was added at day 2 and the culture medium was renewed
every other day. At days 7 and 14, CTLs were restimulated
with overnight peptide-pulsed (10 M) T2-cells, which
were lethally irradiated. The cultures were evaluated at day
21 for the presence of peptide-speciWc expanded CD8+ T-
cells. In vitro stimulation of PBMC with CEA-derived
peptides in microcultures was performed as previously
described [21] using freshly isolated PBMCs at 0.2 £
106 cells/well (96 U-bottom plate) (FALCON, Franklin
Lakes, NJ, USA) in CTL culture medium in the presence
of 10 M of peptide. IL-2 was added at day 2 at 1,000
IU/ml. The medium was changed every other day and the
induction of speciWc CD8+ T-cells was evaluated at day
10.
Multimer-guided cell sorting and cloning
The expansion of CEA peptide-speciWc CD8+ T-cells
stimulated by co-culture with autologous DC or in the pep-
tide-stimulated PBMC microcultures was evaluated by
multicolor Xow cytometry of day 21 or 10, respectively,
employing peptide-MHC multimers. The cultures were har-
vested and washed in PBS 0.2% BSA, 50 mM EDTA (Facs
buVer). PE-conjugated multimers were incubated at room123
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were incubated with FITC-conjugated anti-human CD8
mAb at 4°C during 20 min. Cells were immediately
acquired in a FACsVantage cell sorter. Multimer+ CD8+
cells were electronically gated and sorted at 4°C. Sorted
cells were promptly placed in culture in CTL culture
medium with 150 IU/ml of rhIL-2 overnight. The next day,
sorted cells were cloned by co-culture in limiting dilution
conditions (0.3 cells/well) in NUNCLON plates (NUNC,
Roskilde, Denmark) with 104 irradiated allogenic PBMC,
150 IU/ml of IL-2, and 1 g/ml of phytohemagglutinin-leu-
koagglutinin (PHA-L) (REMEL, Dartford, UK). Proliferat-
ing wells were screened after 7–9 days of culture and
expanded to 96 U-bottom plate wells. Cells were then resti-
mulated with irradiated allogenic PBMCs, IL-2, and PHA-
L as above. Cultures were replenished with media and split
into new plates as required. CTL clones generated were
evaluated with multimers for TCR speciWcity and later for
functional antigen-triggered cytolitic activity.
Chromium release-based cytolytic assay
Cytolytic activity was assessed using a 4 h chromium
release assay. To evaluate the relative avidity for the anti-
gen ligand of the CTL clones generated upon multimer-
guided cell sorting, radiolabeled T2-cells were plated in 96
V-bottom plates and pulsed with a range of peptide concen-
trations (10¡5 to 10¡14 M). Cells were incubated with pep-
tide at least 1 h before addition of cloned CTL at an eVector
to target cell ratio of 10:1. In tumor recognition assays,
“hot” targets were co-cultured with T-cell clones at diVer-
ent eVector to tumor cell ratios. About 50 IU/ml of IFN-
(R&D Systems) was added to tumor cells culture medium
during 72 h prior to some tumor recognition assays. Na51Cr
released in the media was quantiWed using LumaPlate-96
plates (PerkinElmer, Wellesley, MA, USA) and a Top-
Count--counter (PerkinElmer).
Reverse-transcription and semi-quantitative PCR
Total RNA was extracted with RNeasy Mini Kit (Qiagen,
Hilden, Germany). About 1 g RNA was then reverse-tran-
scribed to cDNA using M-MLV reverse transcriptase
(Invitrogen). The following primers were used for semi-
quantitative polymerase chain reaction (PCR): -actin
forward 5-GGC ATC GTG ATG GAC TCC G-3 reverse
5-GCT GGA AGG TGG ACA GCG A-3; CEACAM3
forward 5-TTG CCA AAA CTG GAA GAA CC-3
reverse 5-AGC CAC TTC TGC TTT GTG GT-3; CEA-
CAM4 forward 5CGC ATA CAG TGG TCG AGA GA-3
reverse 5-TGG GAC GTT GTT TTG GTG TA-3; CEA-
CAM5 forward 5-AAC CCA GAA CCC AGT GAG TG-
3 reverse 5-ATT GCT GGA AAG TCC CAT TG-3.
Thermocycling conditions for CEACAM3, CEACAM4,
and CEACAM5 were the following: 94°C, 15; 25 £ (94°C
15, 60°C 30, 72°C 60), 72°C 10, 4°C pause. All reac-
tions were performed in a T3 thermocycler (Biometra,
Göttingen, Germany). PCR products were visualized by
electrophoresis on agarose gel stained with ethidium bro-
mide.
Results
Peptide CEA694–702 is poorly immunogenic and displays 
low-binding activity to HLA-A*0201 molecules
Labeling of PBMC samples from Wve HLA-A2+ healthy
donors with A2/CEA694–702 multimers in conjunction with
anti-hCD8 antibody did not detect CEA694–702-speciWc
T-cells (not shown). The threshold of detection could be
Wxed at 0.07 § 0.02%—a value comparable to the values
determined for other HLA-A2/peptide multimers used in
our laboratory [37]. To probe the potential immunogenicity
of peptide CEA694–702, we performed multiple in vitro stim-
ulations of PBMCs from HLA-A*0201+ healthy donors and
evaluated the presence of expanded peptide-speciWc CD8+
T-cells by labeling with A2/CEA694–702 multimers and Xow
cytometry. As demonstrated in Fig. 1a and summarized in
Table 1, the peptide CEA694–702 did not generate detectable
peptide-speciWc responses either after stimulation of PBMC
with peptide and IL-2, or after multiple stimulations of
puriWed CD8+ T-cells with autologous peptide-pulsed den-
dritic cells.
A major determinant of peptide immunogenicity is its
ability to stably bind to the presenting MHC molecule.
Therefore, we determined CEA694–702 peptide’s aYnity and
stability to HLA-A*0201 molecules using in silico and
in vitro methods. As shown in Table 2, the native CEA694–702
peptide was predicted to have relatively low-aYnity scores
when compared with a known viral epitope (HIVpol589–597,
a good binder to HLA-A*0201) [39]. These predictions
were conWrmed experimentally (Table 2). CEA694–702 pre-
sents low capacity to stabilize cell surface HLA-A*0201 on
T2-cells: it presented bad relative aYnity scores (RA > 10)
and formed short lived complexes with HLA-A2 (t < 1 h).
Analogs of peptide CEA694–702 have higher 
HLA-A*0201-binding capacities
Because of the low aYnity of peptide CEA694–702, we designed
three peptide analogs incorporating canonical HLA-
A*0201 anchor residues (leucine at position 2 and/or valine
at position 9). These peptides with sequences GLLVG-
VALI, GVLVGVALV, and GLLVGVALV will be termed
CEA694L2, CEA694V9, and CEA694L2V9, respectively.123
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introduced into the peptide sequence, their binding to
HLA-A2 improved substantially as reXected by their
enhanced ability to stabilize surface HLA-A2 expression in
T2-cells (Table 2). Moreover, CEA694L2, CEA694V9, and
CEA694L2V9 analog peptides showed relative aYnity val-
ues 8–24 times higher than the wild-type peptide. The
CEA694L2V9 variant presented the highest aYnity. More-
over, the CEA694L2V9 and CEA694V9 and to a lesser
degree CEA694L2 peptide analogs substantially increased
the stability of surface HLA-A2 expression at 37°C. In
summary, CEA694–702 peptide analogs have increased aYn-
ity to HLA-A*0201 MHC class-I allele as compared to the
wild-type peptide.
CEA694–702 peptide analogs stimulate speciWc T-cells
A new series of in vitro stimulation with several human
HLA-A*0201 healthy donors PBMCs were performed to
assess the immunogenicity of the CEA694L2, CEA694V9,
and CEA694L2V9 peptide analogs. As depicted in Fig. 1b
and summarized in Table 1, the CEA694–702 peptide analogs
lead to vigorous expansion of peptide analog-speciWc CD8+
T-cells, in clear contrast to the native CEA694–702. In particular,
Fig. 1 Immunogenicity of CEA694–702WT and analog peptide in
HLA-A*0201 healthy donors. a PBMCs from three HLA-A*0201
healthy donors were stimulated Wrst with peptide-pulsed autologous
matured dendritic cells and two consecutive times with irradiated T2-
cells pulsed with peptide CEA694–702WT. The presence of peptide-spe-
ciWc CD8+ T-cells was assessed by multiparameter Xow cytometry
analysis 1 week after the last restimulation on cultured cells labeled
with anti-CD4 mAb and A2/CEA694–702 multimers. b Representative
results from PBMC of one HLA-A*0201 healthy donor stimulated
with peptide CEA694–702L2 (left), CEA694–702V9 (center), and CEA694–702
L2V9 (right) independently. Flow cytometry analysis was performed
after three rounds of in vitro stimulation with anti-CD8 mAb and the
corresponding A2/cognate peptide multimers
Table 1 Immunogenicity of CEA694–702 and altered peptide ligands
All experiments were performed by in vitro stimulation of PBMCs
from nine HLA-A*0201 positive healthy donors with the indicated
peptides
a In vitro stimulation was carried out in multiple parallel PBMC
microcultures as described in Materials and methods
b In vitro stimulation was carried out by co-culture of puriWed CD8+
T-cells and autologous peptide-pulsed DCs and peptide-pulsed T2-
cells at a ratio of 5:1
c After 10 days of microculture or three rounds of in vitro stimulation
(DC based), cells were labeled with anti-CD8 and A2/CEA peptide
multimers. A culture was considered as positive when the number of
CD8 A2/CEA peptide multimer cells was higher than 0.1% of CD8+
T-cells
Peptide In vitro
expansion 
method
Number of 
signiWcant 
expansionsc
Number 
of cultures
tested
CEA694–702WT Microculturea 0 4
DC basedb 0 5
CEA694–702L2 Microculture 3 4
DC based 2 5
CEA694–702V9 Microculture 0 4
DC based 1 5
CEA694–702L2V9 Microculture 3 4
DC based 2 5123
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ited more frequently detectable responses and independent
of the method of in vitro expansion used.
Cloned CD8+ T-cells speciWc for the CEA694L2 analog 
eYciently cross-recognize the native CEA694–702 peptide
Using multimer-guided cell sorting and limiting dilution
techniques, we isolated CD8+ T-cell clones speciWc for
each of the CEA694–702 peptide analogs. Only stable CD8+
T-cell clones were obtained upon sorting with A2/
CEA694L2 multimers (n = 11). Other clones isolated with
A2/CEA694, A2/CEA694V9, or A2/CEA694L2V9 multi-
mers were not speciWc or with very limited proliferative
capacity and, therefore, detailed characterization was not
possible. Thus, all functional assays were conducted using
CTL clones obtained with CEA694L2-speciWc multimers.
We Wrst assessed the level of cross-reactivity between
native (CEA694–702) and the analog (CEA694L2) peptides
by staining the CEA694L2-speciWc CD8+ T-cell clones
with HLA-A2 multimers incorporating either CEA694–702 or
CEA694L2 peptides. As shown in Fig. 2a, the clone no. R1,
representative of all clones analyzed, is eYciently labeled
by the two multimers, albeit the intensity of the Xuorescent
signal was higher when stained with the A2/CEA694L2
speciWc multimer. This observation suggests the higher
TCR avidity for the peptide analog-MHC complex [45].
We then assessed the level of functional cross-reactivity
between the CEA694–702 and CEA694L2 peptides in a chro-
mium release assay. As depicted in Fig. 2b, the representa-
tive T-cell clone no. R1 recognized and lysed peptide
sensitized HLA-A2+ T2-cells eYciently. Half maximal
lysis was observed at analog peptide concentrations ranging
between 1 and 10 nM for all the clones tested (n = 11).
Recognition of the native peptide was equally eYcient. We
also extended the analysis of CEA antigen cross-reactivity
to naturally occurring CEA694–702 peptides present in other
CEA family members. These include GVLVGVALV,
which in fact is identical to one of the designed peptide
analogs described above—CEA694V9 (CEACAM3 and
CEACAM4), GVVALVALI (CEACAM1), GVLARVALI
(CEACAM6 and CEACAM8), and GVLAGMALI (CEA-
CAM7). As shown in Fig. 2c, only the GVLVGVALV
analog was cross-recognized by the CEA694L2 peptide-
speciWc no. R1 T-cell clone, thus suggesting the potential
capacity to recognize CEACAM3-, CEACAM4-, and
CEACAM5-derived antigens.
These results show that the clone CEA694–702L2 no. R1 is
cross-reactive to native and high HLA-A2 aYnity peptide
analogs with intermediate to low-functional avidity.
Tumor-cell recognition by CEA-speciWc CTL clones
We next assessed the ability of peptide analog-speciWc
cloned CD8+ T-cells to recognize CEA-expressing human
tumor cell lines. We Wrst evaluated the expression levels of
CEACAM3, CEACAM4, and CEACAM5 in the tumor cells
by semi-quantitative RT-PCR. As shown in Fig. 3a,
CEACAM3 and CEACAM4 were found to be selectively
expressed by granulocytes isolated from human PBMC [18,
22]. None of the epithelial cell lines tested detectably
expressed those transcripts by semi-quantitative PCR. In
contrast, several epithelial tumor cell lines expressed CEA-
CAM5 mRNA especially SW403, KATOIII, and LOVO.
The expression in those cells was higher or equal to -actin
expression levels. CEACAM5 was undetectable in HCT-
116 and SW480. Other cell lines such as SW620,
COLO201, SW1116, and T84 expressed relatively low
Table 2 Predicted and experimental peptide binding to HLA-A*0201
a Each peptide sequence was entered into the BioInformatics and Molecular Analysis Section (BIMAS [26]) or the SYFPEITHI [30] algorithms.
The HLA-A2 binding score output is annotated in the corresponding columns
b Values are the ratio between anti-HLA-A2 mean Xuorescence intensity measured on T2-cells loaded with saturating concentrations of peptide
in serum-free media and non-loaded T2-cells
c RA-relative HLA-A2 aYnity values, which are calculated as described in the Materials and methods section
d Stability DC50 is the number of hours required to attain half maximal anti-HLA-A2 Xuorescence at the surface of T2-cells at 37°C after removal
of peptide from media
Peptide BIMASa SYFPEITHIa MFI ratio  (n = 5)b RA (n = 4)c Stability DC50 (h)d
GVLVGVALI CEA694–702WT 8 23 0.92 § 0.37 23.74 § 14.12 <1
GLLVGVALI CEA694–702L2 89 29 1.18 § 0.39 3.15 § 3.82 1–2
GLLVGVALV CEA694–702V9 52 25 1.87 § 0.39 2.23 § 0.89 2–4
GLLVGVALV CEA694–702L2V9 592 31 1.78 § 0.19 0.98 § 0.17 4–6
GVLARVALI CEA694AR4 8 21 n.d. n.d. n.d.
GVLAGMALI CEA694AGM4 8 19 n.d. n.d. n.d.
GVVALVALI CEA694VAL3 8 20 n.d. n.d. n.d.
IVGAETFYV HIVpol589–597 330 18 3.28 § 0.61 – n.d.123
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tein expression were evaluated by Xow cytometry with a
pan-CEA-speciWc antibody (data not shown).
We then assessed the ability of no. R1 T CTL clone to
recognize and lyse tumor cell lines. As shown in Fig. 3b,
the clone was able to recognize and eYciently kill all HLA-
A*0201 tumor cell lines pulsed with the native CEA694–702
peptide. However, in the absence of exogenously added
peptide, it only killed the SW403 colon cancer cell line.
Close to background lysis levels were observed for KATO
III (HLA-A2+), COLO201 (HLA-A2+), and SW620 (HLA-
A2+). Importantly, SW1116 (HLA-A2+), the cell line from
which the peptide CEA694–702 was eluted, was not recog-
nized. A similar deWciency of recognition and lysis was
observed with the T84 and SW480 tumor cell lines. As
expected, background levels of lysis were present with the
cell lines LOVO (HLA-A2¡), Me 290 (HLA-A2 melanoma
cell line, CEA¡), and K562 (NK sensitive). We further
evaluated the speciWcity of recognition of the SW403 cell
line using a cold-target inhibition of cell lysis assay. As
Fig. 2 Fine speciWcity of CEA analog peptide-speciWc T-cells. a A2/
CEA694–702WT and A2/CEA694–702L2 multimer staining proWle of
CEA694–702L2 no. R1 CTL clone. b CEA694–702WT and CEA694–702L2
peptide recognition eYciency of the same CTL clone. c EYciency of
recognition of peptide analogs of CEA694–702 derived from CEACAM5
and other family members (CEACAM1—CEA694VAL3, CEA-
CAM3—CEA694V9, CEACAM4—CEA694V9, CEACAM6 CEA694
ARV4, CEACAM7—CEA694AGM4, and CEACAM8—CEA694 ARV4)
by CEA694–702L2 no. R1 CD8+ T-cell clone
Fig. 3 Naturally processed antigen presentation by CEA positive
colorectal carcinoma cell lines. a Semi-quantitative mRNA expression
analysis of human tumor cell lines. The transcripts for -actin, CEA-
CAM3, CEACAM4, and CEACAM5 were ampliWed by RT-PCR from
serially diluted reverse-transcribed total RNA extracted from cell lines.
b Recognition of human tumor cell lines by CEA694–702L2 no. R1
CD8+ T-cell clone in a chromium release assay. Pulsed targets were
loaded with 1 g/ml of CEA694–702 peptide. c Peptide-dependent recog-
nition of SW403 colon cancer cell line assessed by cold-target inhibi-
tion. The ratio cold : hot was 10:1. Cold targets were T2-cells pulsed
with either 1 g/ml of CEA694–702 peptide or 1 g/ml of FluMA58–66
peptide123
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CEA694L2 no. R1 was signiWcantly reduced by the pres-
ence of excess cold-targets (T2-cells) pulsed with CEA694–702
native peptide. In contrast, cold-targets pulsed with an irrel-
evant peptide did not inhibit lysis of SW403, thus conWrm-
ing the peptide speciWcity of the observed tumor cell lysis.
We also tested the recognition of HLA-A*0201 positive
granulocytes by both the T-cell clone and polyclonal
CEA694L2-speciWc CTLs in cytolytic assays. However, no
evidence of T-cell recognition could be detected even in the
presence of exogenously added native CEA694–702 peptide
(data not shown).
Overall, these results show that peptide CEA694–702 can
be processed and presented by tumor cells lines expressing
HLA-A*0201 and high levels of CEACAM5.
Analysis of CEA694–702-speciWc CD8+ T-cell responses 
in colon cancer patients
We next addressed the existence of CEA694–702-speciWc
CD8+ T-cell responses in a group of HLA-A2+ colon cancer
patients. To assess the possible existence of high frequen-
cies of CEA694–702-speciWc CD8+ T–cells, we labeled
PBMCs from three HLA-A*0201 colon cancer patients
with A2/CEA694–702L2 multimers. As summarized in Table 3,
none of the three cancer patients had detectable
CEA694L2-speciWc CD8+ T-cells ex vivo. However, after a
single stimulation of PBMCs with peptide CEA694L2,
CEA694L2-speciWc CD8+ T-cells signiWcantly expanded in
two of three patients to numbers as high as 3% of the total
CD8+ T-cell population. The patient that failed to respond
to the stimulation protocol also showed no detectable
expansion of FluMA58–66 peptide-speciWc CD8+ T-cells,
suggesting low responsiveness of the T-cells. PBMCs stim-
ulated with the immunogenic HLA-A*0201-restricted pep-
tide NY-ESO-1157–165 did not generate CEA694L2-speciWc
CD8+ T-cells, demonstrating the antigen speciWcity of the
induced T-cells (Fig. 4a).
These results reveal the presence of CEA694–702-speciWc
T-cells in the peripheral blood of cancer patients that can be
mobilized and expanded using peptide analogs of higher
HLA-A*0201 aYnity.
We further extended the study of these in vitro responses
by CEA694L2 multimer-speciWc guided cell sorting and
establishment of CD8+ T-cell clones by limiting dilution.
These clones were then characterized for their cross-recog-
nition of the native peptide. As shown in Fig. 4b, a surpris-
ingly low eYciency of antigen recognition was recorded for
the great majority of the T-cell clones evaluated in native
peptide titration assays. They attained half maximal lysis
with concentrations of native CEA694–702 peptide that were
approximately one log higher than those required by CTL
clones isolated from PBMC of healthy donors (Fig. 2b). At
the same time, these series of T-cell clones obtained from
cancer patients displayed a marked high level of recogni-
tion eYciency of the CEA694L2 analog peptide. The
reduced cross-recognition activity of these CTL clones and
their lower lytic eYciency forecasted a reduced or complete
abrogation of tumor-cell recognition. Cytolytic assays were
performed with multimer-sorted bulk T-cell populations
and several T-cell clones of diVerent avidities (Fig. 4c). The
results obtained conWrmed our expectations on the potential
failure of the CTL clones generated from cancer patients, as
these CTL were unable to recognize tumor cells expressing
CEA antigen even when treated with IFN- for 72 h, a
treatment commonly used to increase HLA class-I expres-
sion [35].
Discussion
We have addressed the potential immunogenicity of a
CEA-derived non-apeptide identiWed 6 years ago as an
HLA-A2 binding peptide [33]. The promise of this peptide
as a bona Wde tumor-associated antigen stemmed from the
evidence that the peptide is naturally processed. Indeed, the
peptide was found via the biochemical analysis of the pool
of peptides eluted from MHC class-I molecules that had
been puriWed from an HLA-A2+ colorectal carcinoma cell
line. Our experimental analysis lead to the following
conclusions: (1) the native peptide binds weakly to the
HLA-A2 molecule and is poorly immunogenic in an
in vitro culture system, (2) introduction of the two major
anchors for HLA-A2 substantially improves both binding
Table 3 Immunogenicity of CEA694–702L2 peptide in HLA-A*0201
colon cancer patients
n.d. not done
a Ex vivo Xow cytometry analysis of CD8+  A2/CEA694L2
multimer+  T-cells in PBMC analysis
b PBMCs from HLA-A*0201 colon cancer patients were stimulated
with peptide CEA694–702L2 at 10 g/ml. rIL-2 at 1,000 IU/ml was add-
ed 48 h after stimulation and every other day after that. Anti-CD8 and
A2/CEA694L2 multimer analyses were performed at day 10. The Wg-
ures represent the percentage of CD3+  CD8+ multimer+  events
c 57 years old, TMN: pT4 pN1 Mx
d 56 years old, TMN: pT4 pN2 pMx
e 57 years old, TMN pT4 pN2 pMx
Peptide Ex vivoa In vitrob
LAU 
892c
LAU 
896d
LAU 
919e
LAU 
892
LAU 
896
LAU 
919
Irrelevant n.d. n.d. n.d. 0.4 0.1 0.6
FluMA58–66 <0.07 <0.07 n.d. 0.6 6.4 76.6
CEA694L2 <0.07 <0.07 <0.07 0.2 3.2 2.4123
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log-speciWc CTL clones generated from healthy donor lym-
phocytes can be tumor reactive and display intermediate
functional TCR avidity, and (4) peptide analog-speciWc
CTL generated from colorectal carcinoma patients have a
signiWcantly lower TCR avidity for cross-recognition of the
native CEA694–702 peptide and fail to recognize tumor cells
expressing both HLA-A2 and CEA.
In contrast to the so-called direct immunology approach
to identify CTL-deWned tumor antigens [14, 42], where
tumor cell lysis by CTLs already proves that naturally pro-
cessed antigen is recognized and can trigger CTLs, both
reverse immunology [43] and biochemical methods for
identiWcation of T-cell epitopes [29, 33] require proof that
the hypothetical antigenic candidates are naturally pro-
cessed and immunogenic. In this regard, for several tumor
antigen candidates, contradictory data have been reported
concerning peptide immunogenicity, presentation by tumor
cells, and tumor cell peptide-speciWc CTL tumor recogni-
tion [2, 4, 7, 19, 27, 31, 32, 41, 44]. Therefore, it is critical
for the appropriate validation of tumor-derived CD8+ T-
cell epitopes that reproducible data on the antigen process-
ing, immunogenicity, functional performance of induced
CTLs, and tumor cell recognition are provided.
From the list of eluted peptides, reported by Shirle
et al., the previously unknown peptide CEA694–702 was
described [33]. Surprisingly, other previously known
CEA HLA-A*0201 CD8+ peptides were not detected,
raising doubts concerning the eYciency of their antigen
processing. However, peptides may be present at too low
numbers, or other reasons may account for lack of peptide
identiWcation by biochemical analysis of material
obtained with acid elution.
Our Wndings pose a paradox: that a peptide with low
aYnity for HLA-A*0201 and forming unstable complexes
could be successfully identiWed from the mixture of MHC
class-I eluted peptides, in both a tumor cell line and a tumor
tissue fragment [33]. Nevertheless, successful identiWcation
of naturally processed peptides with low aYnity to HLA-
A2 molecules has been reported [36]. It is conceivable that
the original eluted fraction from which the peptide was
identiWed was composed of a mix of closely related peptide
analogs, which provided fragment signals leading to the
CEA694–702 sequence prediction. However, screening for
HLA-A*0201-binding natural CEA694–702 analogs in human
protein databases consistently provided CEA family-related
protein-derived peptides (CEACAM1436–444: GVVALVALI,
CEACAM3159–167: GVLGVGALV, CEACAM4159–167:
GVLGVGALV, CEACAM5694–702: GVLVGVALI, CEA-
CAM6336–344: GVLARVALI, CEACAM7257–265: GVLAG-
MALI, and CEACAM8341–349: GVLARVALI). Among
these, only the GVLVGVALI and GVLVGVALV peptides
were cross-recognized by the CEA694L2 no. R1 clone
Fig. 4 Immunogenicity of the CEA694–702L2 peptide analog in HLA-
A*0201 colon cancer patients and tumor reactivity of CD8+ T-cell
clones. a PBMCs from three HLA-A2 colon cancer patients were
stimulated with 10 g/ml of peptide and cultured for 10 days in
1,000 IU/ml IL-2. FluMA58–66 and NY-ESO-1157–165 peptides were
used as controls of peptide-speciWc CTL induction. Cells were la-
beled with the indicated A2 multimer and anti-CD8 mAb. Data is
summarized in Table 3. b CEA694–702WT and CEA694–702L2 peptide
recognition eYciency of the 18 patient-derived CTL clones generated
from A2/CEA694–702 multimers-guided cell sorting and limiting dilu-
tion. c Tumor-cell recognition of tumor cell lines expressing CEA
antigen. Left panel shows CD8+ T-cell functional avidity of poly-
clonal and clonal populations. Center panel presents histograms of
tumor recognition in chromium release assay unpulsed or pulsed with
CEA694–702 peptide. Right panel shows CTL recognition of tumor
cells unpulsed or pulsed with CEA694–702 peptide but pre-treated for
72 h with IFN-123
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nized and are predicted as very weak binders to HLA-
A*0201 (Table 2).
Furthermore, the semi-quantitative PCR analysis sug-
gests that CEACAM5 is the likely source of the peptide
present in the peptide elution pool, as all colon epithelial
tumor cells, including the SW1116 cell line, expressed
detectable amounts of the CEACAM5 cDNA. Moreover,
CEACAM3 and CEACAM4, which code for cross-recog-
nized peptides with GVLVGVALI, are not expressed by
tumor cell lines (Fig. 3a). Alternatively, it can be hypothe-
sized that the oV-rate of the low-aYnity peptide CEA694 is
compensated by a high rate of antigen synthesis, proteoly-
sis, and derived peptide presentation at the cell surface [28,
46]. It is interesting to note that the CEA694-702 epitope is
located at the carboxyl terminus of CEACAM5, which
ensures its release in the cytoplasm by proteasomal degra-
dation [11].
The expression of CEACAM5 in epithelial tissues may
likely result in the induction of both central and peripheral
tolerance [17], as has been previously described for other
tumor-associated antigens, e.g., p53, gp100 [15, 24]. Our
Wndings are in agreement with the hypothesis that tolerance
to CEA antigen may exist in humans. First, the immuno-
genic CEA peptide analogs display diVerential CTL induc-
tion eYciency, as their relative immunogenicity does not
strictly correlate with their relative HLA-A*0201-binding
capacity. Second, the peptide-speciWc CD8+ T-cell clones
all had low to intermediate TCR avidities irrespective of
whether they had been induced by CEA694L2, CEA694V9,
or CEA694L2V9. In addition, clones derived by stimula-
tion with the CEA694V9 and CEA694L2V9 had a very
limited proliferation capacity. Moreover, other independent
studies with diVerent CEACAM5-derived peptides have
also reported low to intermediate TCR avidities [47]. Third,
CD8+ T-cell clones generated from colon cancer patients
had in general lower avidity toward the CEA694–702 peptide
than CD8+ T-cell clones generated from human healthy
donors and were unable to recognize CEACAM5 express-
ing tumor cells even when treated with IFN-. These results
suggest that tumor-derived CEA may drive in parallel both
the expansion of CEA694–702-speciWc CD8+  T-cells in vivo
and the deletion of T-cells with relatively high-TCR avid-
ity. The fact that these patients often present high levels of
CEA antigen in their serum might contribute to these
processes.
Altogether, the present Wndings raise serious concerns
on the eYcacy of immunological tumor surveillance pro-
vided by the CEA694–702-speciWc CD8+ T–cells; particularly
because the native epitope is poorly immunogenic, the spe-
ciWc T-cell repertoire induced by peptide analogs shows
low avidity in colon cancer patients and fails to recognize
allogenic tumor cells expressing CEACAM5.
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